BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31378021)

  • 1. [The study of pleural effusion supernatant cell-free tumor DNA in tumor mutational burden assessment of advanced lung cancer].
    Tong L; Ding N; Li JM; Xu XB; Zhang Y; Ye MS; Li C; Zhang X; Hong QY; Zhou J; Bai CX; Hu J
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Aug; 42(8):596-601. PubMed ID: 31378021
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
    Tong L; Ding N; Tong X; Li J; Zhang Y; Wang X; Xu X; Ye M; Li C; Wu X; Bao H; Zhang X; Hong Q; Song Y; Shao YW; Bai C; Zhou J; Hu J
    Theranostics; 2019; 9(19):5532-5541. PubMed ID: 31534501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing.
    Yu Y; Qian J; Shen L; Ji W; Lu S
    Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
    Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
    Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients.
    Kawahara A; Fukumitsu C; Azuma K; Taira T; Abe H; Takase Y; Murata K; Sadashima E; Hattori S; Naito Y; Akiba J
    Cytopathology; 2018 Apr; 29(2):150-155. PubMed ID: 29363841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Non-Small Cell Lung Cancer.
    Liu N; Sun RZ; Du J; Dong QZ; Fan CF; Li QC; Wang EH; Liu Y
    Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):e44-e51. PubMed ID: 28800007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing.
    Lin J; Gu Y; Du R; Deng M; Lu Y; Ding Y
    Int J Clin Exp Pathol; 2014; 7(12):8813-22. PubMed ID: 25674250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
    Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
    Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
    Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
    Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.
    Chen X; Li K; Liu Z; Gai F; Zhu G; Lu S; Che N
    Cancer Med; 2021 Apr; 10(7):2286-2292. PubMed ID: 33656807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of real-time PCR method for detection of EGFR mutation using both supernatant and cell pellet of malignant pleural effusion samples from non-small-cell lung cancer patients.
    Shin S; Kim J; Kim Y; Cho SM; Lee KA
    Clin Chem Lab Med; 2017 Oct; 55(12):1962-1969. PubMed ID: 28306520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
    Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling.
    Guo Z; Xie Z; Shi H; Du W; Peng L; Han W; Duan F; Zhang X; Chen M; Duan J; Lin J; Chen X; Lizaso AA; Han-Zhang H; He J; Yin W
    Thorac Cancer; 2019 Apr; 10(4):823-831. PubMed ID: 30779318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden.
    van den Heuvel GRM; Kroeze LI; Ligtenberg MJL; Grünberg K; Jansen EAM; von Rhein D; de Voer RM; van den Heuvel MM
    Respir Res; 2021 Nov; 22(1):302. PubMed ID: 34819052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor mutational burden and efficacy of chemotherapy in lung cancer.
    Song J; Yan Y; Chen C; Li J; Ding N; Xu N; Bao H; Zhang X; Hong Q; Zhou J; Shao YW; Song Y; Tong L; Hu J
    Clin Transl Oncol; 2023 Jan; 25(1):173-184. PubMed ID: 35995891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.
    Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
    J Immunother Cancer; 2019 Apr; 7(1):98. PubMed ID: 30944026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-free DNA From Pleural Effusion Samples: Is It Right for Molecular Testing in Lung Adenocarcinoma?
    Mokánszki A; Bádon ES; Mónus A; Tóth L; Bittner N; Méhes G
    Pathol Oncol Res; 2021; 27():613071. PubMed ID: 34257581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.
    Schuurbiers M; Huang Z; Saelee S; Javey M; de Visser L; van den Broek D; Heuvel MVD; Lovejoy AF; Monkhorst K; Klass D
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
    Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
    JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
    Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
    BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.